The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment and overall survival (OS) in metastatic renal cell carcinoma (mRCC): A Swedish population-based study (2000-2008).
Ulrika Harmenberg
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Sven Lundstam
Honoraria - GlaxoSmithKline; Pfizer; Roche
Research Funding - Pfizer; Wyeth
Thomas Wahlgren
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Jan Kowalski
Consultant or Advisory Role - Pfizer
Maria Jakobsson
Employment or Leadership Position - Pfizer
Rickard Sandin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Börje Ljungberg
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer
Per Sandström
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer
Honoraria - Bayer Schering Pharma; GlaxoSmithKline; Pfizer
Research Funding - Bayer Schering Pharma; Pfizer